NuVasive, Inc. (NUVA) Releases FY14 Earnings Guidance
NuVasive, Inc. (NASDAQ:NUVA) issued an update on its FY14 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of $1.11 for the period, compared to the Thomson Reuters consensus estimate of $1.12, American Banking News reports. The company issued revenue guidance of $745 million, compared to the consensus revenue estimate of $730.92 million.
NuVasive, Inc. (NASDAQ:NUVA) traded down 0.10% on Tuesday, hitting $35.055. The stock had a trading volume of 365,140 shares. NuVasive, Inc. has a one year low of $22.44 and a one year high of $39.89. The stock has a 50-day moving average of $34.48 and a 200-day moving average of $35.39. The company’s market cap is $1.633 billion.
NuVasive (NASDAQ:NUVA) last released its earnings data on Tuesday, July 29th. The company reported $0.28 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.25 by $0.03. The company had revenue of $190.70 million for the quarter, compared to the consensus estimate of $177.50 million. During the same quarter in the prior year, the company posted $0.20 earnings per share. The company’s quarterly revenue was up 15.1% on a year-over-year basis. Analysts expect that NuVasive, Inc. will post $1.09 EPS for the current fiscal year.
A number of research firms have recently commented on NUVA. Analysts at Goldman Sachs upgraded shares of NuVasive from a neutral rating to a buy rating in a research note on Wednesday, June 25th. On a related note, analysts at Needham & Company LLC downgraded shares of NuVasive from a buy rating to a hold rating in a research note on Wednesday, May 21st. They now have a $40.00 price target on the stock. Finally, analysts at Canaccord Genuity cut their price target on shares of NuVasive from $51.00 to $48.00 in a research note on Wednesday, April 30th. They now have a buy rating on the stock. Five equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The company currently has an average rating of Buy and an average price target of $40.20.
NuVasive, Inc is a medical device company, that focuses on developing minimally disruptive surgical products and procedures for the spine.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.